Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Results of group-wise radiomic feature-based cancer classifications for molecular breast cancer subtypes (training dataset)

From: Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results

  Luminal A Luminal B HER2-enriched TN All others
Luminal A 84.2%
(MI; 6)
76.7%
(POE; 6)
69.4%
(POE; 7)
60.4%
(MI; 9)
Luminal B 84.2%
(MI; 6)
73.7%
(Fisher; 2)
83.9%
(Fisher; 3)
89%
(POE; 9)
HER2-enriched 76.7%
(POE; 6)
73.7%
(Fisher; 2)
73.5%
(POE; 3)
81.3%
(MI; 9)
TN 69.4%
(POE; 7)
83.9%
(Fisher; 3)
73.5%
(POE; 3)
73.6%
(MI; 9)
All others 60.4%
(MI; 9)
89%
(POE; 9)
81.3%
(MI; 9)
73.6%
(MI; 9)
  1. HER2 human epidermal growth factor receptor 2, MI mutual information, POE probability of error and average correlation, TN triple negative. The feature selection algorithm and number of features used for classification are given in parentheses